1. Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):1690.
2. U.S. Food and Drug Administration. Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for delivery at the Brookings Institution on the release of the FDA’s Biosimilars Action Plan. FDA. https://www.fda.gov/news-events/press-announcements/remarks-fda-commissioner-scott-gottlieb-md-prepared-delivery-brookings-institution-release-fdas. Accessed 23 Apr 2020.
3. Patient Protection and Affordable Care Act of 2010. Pub L No. 111-148, 124 Stat 119.
4. Drug Price Competition and Patent Term Restoration Act of 1984. Pub L No. 98-417, 98 Stat 1585.
5. U.S. Food and Drug Administration. Biosimilars Action Plan: balancing innovation and competition. FDA. https://www.fda.gov/media/114574/download. Accessed 23 Apr 2020.